Merck KGaA Stock
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | -0.900% | -0.606% | -8.343% | -33.256% | -17.499% | -31.483% | 13.215% |
| Bayer AG | -1.820% | 3.239% | 10.546% | -0.073% | 41.947% | -56.767% | -58.457% |
| Johnson & Johnson | 0.440% | 0.000% | 2.548% | 0.473% | -2.200% | -17.101% | 7.747% |
| Elanco Animal Health Inc. | -1.080% | 0.278% | 5.189% | -27.370% | 6.027% | -42.191% | -37.848% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
Merck Stock: Solid Q1 Overshadowed by Lowered Outlook
Merck KGaA delivered impressive first-quarter results for 2025, with net profit climbing 5.5% to €738 million and earnings per share reaching €1.69, representing a 5.6% increase compared to the same
2 Beaten-Down Stocks That Are Great Buys on the Dip
Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current environment aren't that different, at least for those focused on the long game
Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now
One great thing about a crash or downturn in the markets is that it can allow you to go bargain hunting fairly easily. Many stocks have been falling this year, and if you're a dividend investor, you